DEF: GE HealthCare Details 2026 Annual Meeting, Governance, and 2025 Performance

GE HealthCare Technologies Inc. has released its 2026 Proxy Statement, outlining proposals for its upcoming annual meeting, executive compensation for 2025, and corporate governance updates.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on May 7, 2026, at 8:00 a.m. Central Time, with a record date of March 9, 2026.
• Stockholders will vote on the election of 8 director nominees, the advisory approval of Named Executive Officers' (NEOs) 2025 compensation, and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026.
• Two incumbent directors, Dr. Risa Lavizzo-Mourey and Dr. Tomislav Mihaljevic, will not stand for re-election due to other commitments, reducing the Board size to 8 directors.
• The company reported strong 2025 financial performance, including $20.6 billion in revenues (up 4.8% year-over-year) and $20.4 billion in Organic revenue (up 3.5% year-over-year).
• Net income attributable to GE HealthCare was $2.1 billion, Adjusted EBIT was $3.2 billion, Diluted EPS was $4.55, and Adjusted EPS was $4.59.
• Cash from operating activities reached $2.0 billion, and Free cash flow was $1.5 billion, closing the year with a record backlog and solid book-to-bill.
• The executive compensation program for 2025 saw a 101% payout for corporate-level annual bonuses and a 95% payout for 2023 Performance Stock Units (PSUs), adjusted for tariff impacts.
• The CEO's total compensation for 2025 was $18,562,794, with a pay ratio of 241 to 1 compared to the median employee.
• Corporate governance highlights include a majority of independent directors (7 out of 8 nominees), annual director elections by majority vote, a 15-year term limit for directors (excluding the CEO), and robust stock ownership requirements for executives and directors.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively, reflecting strong 2025 financial performance, robust corporate governance, and effective management of external challenges, which collectively contribute to a stable and well-managed company outlook.

Positives

• Reported strong 2025 financial performance with revenues of $20.6 billion (up 4.8% YoY) and Organic revenue of $20.4 billion (up 3.5% YoY).
• Achieved $2.1 billion in Net income, $3.2 billion in Adjusted EBIT, $4.55 Diluted EPS, and $4.59 Adjusted EPS for 2025.
• Generated $2.0 billion in cash from operating activities and $1.5 billion in Free cash flow, ending 2025 with a record backlog and solid book-to-bill.
• The 2025 executive compensation program's corporate-level annual bonus payout was 101% of target, reflecting strong performance against financial and strategic goals.
• The 2023 PSU awards paid out at 95% of target, with an upward adjustment from 90% to 95% to account for the net impact of unanticipated external trade-related developments (tariffs), demonstrating effective management mitigation.
• Stockholders showed high support for the 2025 say-on-pay proposal, with 94.4% of votes cast in favor.
• The Board maintains strong corporate governance practices, including a majority of independent directors (7 out of 8 nominees), annual director elections, and robust stock ownership requirements for executives and directors.
• The company has a comprehensive clawback policy and prohibitions against hedging and pledging of company securities.

Negatives

• Two incumbent directors, Dr. Risa Lavizzo-Mourey and Dr. Tomislav Mihaljevic, are not standing for re-election due to other commitments, leading to a reduction in board size.
• The Patient Care Solutions (PCS) segment, led by NEO Jeannette Bankes, achieved a 69% bonus payout, lower than the corporate average, indicating specific segment challenges.
• The company's 2025 performance was impacted by a 'dynamic global environment, including tariffs,' requiring significant mitigation work.

Risks

• The company operates in a dynamic global environment, including tariffs, which can impact financial performance.
• Cybersecurity risks are a key area of oversight for the Audit Committee, requiring ongoing management and strategy processes.
• Risks related to the company's utilization of Artificial Intelligence (AI) in terms of management, compliance, and ethical use are overseen by the Governance Committee.
• The company's forward-looking statements are subject to various risk factors, as detailed in its Annual Report on Form 10-K, which could cause actual results to differ materially from projections.

Future Outlook

The Board remains focused on overseeing the execution of the company's strategy in 2026 to support sustainable growth, enhance profitability, and create stockholder value. The D3 strategy, integrating smart devices and drugs across disease states, enabled by digital, AI, and cloud solutions, continues to differentiate GE HealthCare, aiming to deliver bold innovations for more personalized, precise patient care.

Management Comments

• Frank R. Jimenez, Secretary, cordially invited stockholders to participate in the 2026 Annual Meeting.
• The Board of Directors expressed thanks to Dr. Risa Lavizzo-Mourey and Dr. Tomislav Mihaljevic for their invaluable service and outstanding contributions to the Company since the Spin-Off, as they will not stand for re-election.

Industry Context

StockSavvy.ai notes that GE HealthCare operates as a leading global healthcare solutions provider in a dynamic global environment, including challenges like tariffs. The company's strategic focus on precision care, growth acceleration, and business optimization, underpinned by its D3 strategy (smart devices, drugs, digital, AI, and cloud solutions), positions it to leverage key industry trends. Its commitment to innovation and digital transformation, including AI governance, is crucial for maintaining a competitive edge against peers in the medical technology and pharmaceutical diagnostics sectors.

Comparison to Industry Standards

• GE HealthCare's executive compensation program is evaluated against a 15-company peer group in the medical device and medical technology sectors, including Abbott Laboratories, Danaher Corporation, Koninklijke Philips N.V., Agilent Technologies, Inc., Edwards Lifesciences Corporation, Siemens Healthineers AG, Baxter International Inc., Hologic, Inc., Stryker Corporation, Becton, Dickinson and Company, Intuitive Surgical, Inc., Thermo Fisher Scientific Inc., Boston Scientific Corporation, Medtronic plc, and Quest Diagnostics Incorporated.
• The company's pay-for-performance approach, with 92% of CEO and 83% of other NEOs' target compensation at-risk, aligns with best practices among its peer group, emphasizing long-term value creation.
• The 2025 CEO pay ratio of 241 to 1 provides a benchmark for executive compensation relative to the median employee, which can be compared to similar disclosures from its industry peers.
• The high 94.4% stockholder support for the 2025 say-on-pay proposal indicates strong alignment with investor expectations regarding executive compensation practices, a positive signal compared to potential dissent seen in some industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• A stockholder proposal from Martin Harangozo, received on October 24, 2025, was excluded from the proxy statement. The company determined the proposal was excludable under Rule 14a-8 on procedural and substantive grounds (failure to provide adequate proof of continuous ownership, personal grievance, and substantial implementation). The SEC indicated no objection to the exclusion on January 2, 2026.

Related Party Transactions

• From January 1, 2025, through February 28, 2026, GE HealthCare recognized approximately $50 million in revenue from Cleveland Clinic Foundation and approximately $61 million from Providence for products and services. Dr. Mihaljevic (a director not standing for re-election) is CEO of Cleveland Clinic, and Dr. Hochman (a director) served as CEO of Providence until January 2025. These transactions were conducted in the ordinary course of business on an arms-length basis and were not deemed materially interesting to the directors.

Stakeholder Impact

• Shareholders: Will vote on key governance matters, including director elections and executive compensation, directly influencing company leadership and oversight. The company's strong financial performance and commitment to value creation are beneficial.
• Employees: Benefit from competitive total rewards programs, including base salaries, annual incentives, and long-term equity awards, designed to attract, retain, and motivate talent. The company's focus on culture, belonging, and talent development supports employee well-being.
• Customers: Benefit from the company's continued focus on innovation, digital strategy, and precision care, aiming to deliver advanced medical technology and solutions.
• Suppliers: The company's operational resilience and strategic execution, including managing supply chain sustainability, impact relationships with suppliers.
• Creditors: The company's strong financial health, including $2.0 billion in cash from operating activities and $1.5 billion in free cash flow, provides confidence in its ability to meet financial obligations.
• Regulatory Authorities: The company's adherence to SEC filing requirements, corporate governance principles, and oversight of regulatory matters demonstrates compliance and responsible operation.

Next Steps

• The 2026 Annual Meeting of Stockholders will be held on May 7, 2026, where stockholders will vote on director elections, executive compensation, and auditor ratification.
• The Board intends to appoint a new lead director after the Annual Meeting, following Dr. Risa Lavizzo-Mourey's conclusion of service.
• Kevin A. Lobo will step down from the Parker-Hannifin board following its annual meeting later in 2026, aligning with GE HealthCare's policy on director outside board commitments.
• Management will continue to engage with stockholders throughout the year on governance matters, incorporating feedback into Board decisions.

Key Dates

Recommendation

The filing primarily details routine corporate governance matters, executive compensation, and references previously disclosed strong 2025 financial performance. While the company demonstrates solid operational execution and robust governance practices, the information presented does not introduce new material catalysts or significant negative surprises that would warrant a change in investment posture for a seasoned investor. The positive financial results are already known, and the governance updates are largely expected or minor in impact.

Keywords

GE HealthCare, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Financial Performance, Medical Technology, Pharmaceutical Diagnostics, Artificial Intelligence, Risk Management, Sustainability, Board of Directors, Shareholder Vote